We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM

MedXY Editorial Team•Jan 17, 2026•Cardiology
AficamtenMAPLE-HCMMetoprololMyosin Inhibitors

Highlights

Aficamten monotherapy demonstrated a superior reduction in both resting and Valsalva left ventricular outflow tract (LVOT) gradients compared to metoprolol.

Significant reverse cardiac remodeling was observed with aficamten, including a reduction in left atrial volume index and maximal wall thickness.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM and Complementary TrialsAficamten, a cardiac myosin inhibitor, demonstrated significant improvements in symptoms, diastolic function, and biomarkers in nonobstructive hypertrophic cardiomyopathy across multiple trials, including the pivotal ACACIA-HCM study.Sep 6, 2026Aficamten’s Impact on Cardiac Function and Structure in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from ACACIA-HCM TrialAficamten significantly improves diastolic function and cardiac structure in symptomatic nonobstructive hypertrophic cardiomyopathy, indicating benefits beyond outflow tract gradient reduction.Sep 3, 2026Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized TrialThe MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten Jun 28, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM StudyThe FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.Jun 28, 2026
Echocardiographic Remodeling and Atrial Dynamics with Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM TrialThis exploratory analysis of the ODYSSEY-HCM trial demonstrates that mavacamten induces modest regression of left ventricular hypertrophy and improves diastolic and left atrial function in nonobstructive HCM, despite a 21.5% incidence of reJan 17, 2026
Beyond Beta-Blockers: Aficamten Reinvents First-Line Therapy for Obstructive Hypertrophic CardiomyopathyThe MAPLE-HCM trial demonstrates that aficamten monotherapy provides superior, rapid, and comprehensive clinical benefits compared to the traditional first-line treatment, metoprolol, across multiple disease domains in patients with symptomDec 25, 2025